MedPath

AGI Therapeutics, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

Phase 3
Completed
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Drug: Placebo
Drug: Rezular 15mg
Drug: Rezular
First Posted Date
2007-11-02
Last Posted Date
2009-06-11
Lead Sponsor
AGI Therapeutics, Inc.
Target Recruit Count
711
Registration Number
NCT00552565
Locations
🇺🇸

PPD, Wilmington, North Carolina, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.